8-K: Cidara Reports Strong Q2, CD388 Trial Success

Cidara Therapeutics announced positive Phase 2b trial results for its influenza preventative CD388, significantly strengthening its balance sheet with a $402.5 million public offering.

Summary

• The Phase 2b NAVIGATE clinical trial for CD388, designed to prevent seasonal influenza, met its primary and all secondary efficacy endpoints across all dose groups.
• Single doses of CD388 provided significant protection over 24 weeks: 76.1% for 450mg, 61.3% for 300mg, and 57.7% for 150mg, compared to a 2.8% placebo attack rate.
• CD388 was well-tolerated with no safety signals observed, and a clear dose-response for efficacy was demonstrated.
• An End of Phase 2 meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the planned Phase 3 study design.
• A public offering was closed in June 2025, raising gross proceeds of $402.5 million from the sale of 9,147,727 shares at $44.00 per share, significantly strengthening the balance sheet.
• Cash, cash equivalents, and restricted cash increased to $516.9 million as of June 30, 2025, up from $196.2 million at December 31, 2024.
• Net loss for the second quarter ended June 30, 2025, was $25.7 million, a significant reduction from $91.2 million for the same period in 2024.
• Research and development (R&D) expenses increased to $24.8 million for Q2 2025, up from $6.7 million in Q2 2024, primarily due to CD388 trial and development costs.
• The company was added to the Russell 2000 and Russell 3000 Indexes in June 2025.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to exceptionally strong Phase 2b clinical trial results for the lead candidate CD388, coupled with a highly successful and substantial capital raise that significantly de-risks the company's financial position for its planned Phase 3 program. The reduction in net loss and inclusion in major indexes further bolster confidence.

Positives

• CD388 Phase 2b NAVIGATE trial met primary and all secondary efficacy endpoints, demonstrating strong protection against seasonal influenza (76.1% at 450mg dose).
• CD388 was well-tolerated with no safety signals observed, indicating a favorable safety profile.
• Successfully closed an upsized public offering, raising $402.5 million in gross proceeds, significantly strengthening the company's financial position.
• Cash, cash equivalents, and restricted cash increased substantially to $516.9 million, providing ample funding for the planned Phase 3 program.
• Net loss significantly decreased to $25.7 million in Q2 2025 from $91.2 million in Q2 2024.
• Inclusion in the Russell 2000 and Russell 3000 Indexes enhances visibility with institutional investors.
• Received Investigational New Drug (IND) application clearance for CBO421 in July 2024, expanding the DFC pipeline into oncology.

Negatives

• Collaboration revenue was zero for the three and six months ended June 30, 2025, compared to $0.3 million and $1.3 million for the same periods in 2024, due to the termination of the Janssen Collaboration Agreement.
• Research and development expenses increased significantly to $24.8 million in Q2 2025 from $6.7 million in Q2 2024, reflecting higher costs associated with CD388 development.

Risks

• Unanticipated delays in or negative results from clinical trials and other risks related to clinical development.
• The results of the End-of-Phase 2 meeting with the FDA may not be favorable or may lead to unexpected requirements.
• Delays in action by regulatory authorities could impact development timelines.
• Obstacles associated with the enrollment of patients or other aspects of CD388 or other DFC development.
• Having to use cash in ways other than as expected, potentially impacting the planned Phase 3 program.
• General risks and uncertainties associated with the company's business.

Future Outlook

The company plans to initiate a Phase 3 study for CD388 no later than spring 2026, focusing on high-risk and immune-compromised patients, subject to FDA consultation on the study design. Full primary analysis details from the Phase 2b NAVIGATE trial are expected to be submitted to upcoming scientific conferences in 2025.

Management Comments

• Jeffrey Stein, Ph.D., president and chief executive officer, stated that the highly compelling results of the Phase 2b NAVIGATE trial for CD388 and subsequent financing position the company strongly to execute on its Phase 3 plan.
• Jeffrey Stein emphasized the potential of CD388 as a non-vaccine solution to provide single-dose per season, universal protection against influenza in individuals at greatest risk.

Industry Context

Cidara Therapeutics is developing a novel class of drug-Fc conjugate (DFC) therapeutics, positioning itself in the antiviral and oncology sectors. The positive Phase 2b results for CD388, a non-vaccine influenza preventative, address a significant unmet medical need, particularly for high-risk populations where traditional vaccines may be less effective or contraindicated. This approach could offer a new paradigm for influenza prevention, complementing existing vaccine strategies and potentially offering broader protection against various influenza strains.

Stakeholder Impact

• Shareholders: The successful public offering resulted in dilution but significantly strengthened the company's financial position and reduced future financing risk. Positive clinical trial results for CD388 enhance the long-term value proposition.
• Patients: The positive Phase 2b results for CD388 offer hope for a novel, single-dose, universal preventative for seasonal and pandemic influenza, particularly for high-risk individuals.
• Employees: Continued progress in clinical development and a strong financial position provide stability and opportunities for ongoing research and development.
• Regulatory Authorities: The submission of the End of Phase 2 meeting request to the FDA indicates active engagement with regulatory bodies for the advancement of CD388.

Next Steps

• Submit full primary analysis details from the Phase 2b NAVIGATE trial to upcoming scientific conferences in 2025.
• Engage in an End of Phase 2 meeting with the FDA to discuss the proposed Phase 3 study design for CD388.
• Initiate the Phase 3 study for CD388 no later than spring 2026, focusing on high-risk/co-morbid and immune-compromised patients, subject to FDA consultation.

Key Dates

Recommendation

The filing presents compelling evidence for a 'strong buy' recommendation. The Phase 2b NAVIGATE trial results for CD388 are exceptionally positive, demonstrating high efficacy and a favorable safety profile for a potential universal influenza preventative. This de-risks the primary asset significantly. Furthermore, the successful upsized public offering of $402.5 million has dramatically improved the company's cash position to over $500 million, providing ample runway to fund the critical Phase 3 program without immediate financing concerns. The substantial reduction in net loss and inclusion in Russell indexes further underscore operational improvements and increased market visibility. These factors collectively point to a strong growth trajectory and reduced investment risk for a clinical-stage biotechnology company.

Keywords

Biotechnology, Influenza, Antiviral, CD388, Clinical Trial, Phase 2b, Phase 3, Drug-Fc Conjugate, DFC, Public Offering, Financial Results, SEC Filing, CDTX, Cloudbreak platform, FDA